Cardio-oncology & otherGuideline or statement
Gene Editing Therapy in Cardiovascular Disease: 2026 ACC Scientific Statement
- Scientific statement
Scope
As issued by the authors
Overview of gene editing therapies in CVD for the practicing clinician: basic science, diseases most amenable to initial application (certain variants of hypercholesterolemia and amyloidosis), and inherent challenges incl. societal and ethical implications of high-cost, single-treatment cures
Original publication
Gene Editing Therapy in Cardiovascular Disease: 2026 ACC Scientific Statement. J Am Coll Cardiol. Published 26 March 2026. doi:10.1016/j.jacc.2026.02.5092
Summarised from the published abstract; every number is checked against it